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ABSTRACT P-glycoprotein (MDR-1) is a well-known
transporter that mediates eff lux of chemotherapeutic agents
from the intracellular milieu and thereby contributes to drug
resistance. MDR-1 also is expressed by nonmalignant cells,
including leukocytes, but physiologic functions for MDR-1 are
poorly defined. Using an initial screening assay that included
>100 mAbs, we observed that neutralizing mAbs MRK16,
UIC2, and 4E3 against MDR-1 specifically and potently
blocked basal-to-apical transendothelial migration of mono-
nuclear phagocytes, a process that may mimic their migration
into lymphatic vessels. Antagonists of MDR-1 then were used
in a model of authentic lymphatic clearance. In this model,
antigen-presenting dendritic cells (DC) migrate out of ex-
plants of cultured human skin and into the culture medium via
dermal lymphatic vessels. DC and T cells derived from skin
expressed MDR-1 on their surfaces. Addition of anti-MDR-1
mAbs MRK16, UIC2, or the MDR-1 antagonist verapamil to
skin explants at the onset of culture inhibited the appearance
of DC, and accompanying T cells, in the culture medium by
approximately 70%. Isotype-matched control mAbs against
other DC molecules including CD18, CD31, and major histo-
compatibility complex I did not block. In the presence of
MDR-1 antagonists, epidermal DC were retained in the
epidermis, in contrast to control conditions. In summary, this
work identifies a physiologic function for MDR-1 during the
mobilization of DC and begins to elucidate how these critical
antigen-presenting cells migrate from the periphery to lymph
nodes to initiate T lymphocyte-mediated immunity.
Immune responses in a peripheral organ like skin are initiated
after antigen-presenting cells, particularly dendritic cells (DC),
capture antigens locally and migrate via afferent lymphatic
vessels to draining lymph nodes. T lymphocytes continually
recirculate through lymph nodes, so the newly arrived, antigen-
bearing DC become positioned to select lymphocytes that bear
receptors for the presented antigens (1). For example, when
skin is transplanted (2), or a contact allergen such as poison ivy
is applied (3), epidermal DC (also termed Langerhans cells)
migrate from their epithelial locations and carry antigens or
allergens to the lymph node. If the lymphatic conduits to the
draining lymph nodes are severed, the immune system does not
become primed to the antigen (2). As they migrate, the DC
undergo maturation, increasing their expression of molecules
involved in antigen presentation, including major histocom-
patibility complex (MHC) II products, CD80 (B7–1), and
CD86 (B7–2) (4, 5).
Models for the induced emigration of DC and T lympho-
cytes from the periphery have been developed by using
cultured explants of skin. Beginning within 1–2 days after the
onset of culture, DC in the explanted skin migrate into dermal
lymphatics (6) and emerge via these conduits into the culture
medium, along with T lymphocytes (7, 8). Here we describe
that antagonism of p-glycoprotein (MDR-1), a molecule well
known for its ability to transport of a broad spectrum of
xenobiotics out of cells and thereby induce drug resistance (for
review see ref. 9), blocks the migration of DC and T lympho-
cytes out of cultured human skin explants. Thus, these data
identify a unique physiologic function for MDR-1.
MATERIALS AND METHODS
Transendothelial Migration Assays. By using a method
detailed previously (10, 11), freshly isolated peripheral blood
mononuclear cells (PBMC), approximately one-fourth of
which are monocytes, were added to confluent monolayers of
unstimulated human umbilical vein endothelial cells
(HUVEC) grown on type I bovine collagen gels with or
without addition of mAb. Cultures were incubated for 1.5 hr;
during this time, monocytes, but very few lymphocytes, trans-
migrate into the collagen (10). To examine their subsequent
basal-to-apical transendothelial migration, monocytes were
allowed to accumulate beneath the endothelium in the absence
of added mAb. Then monolayers were washed twice in Me-
dium 199 (Life Technologies, Grand Island, NY) to remove
nonadherent cells from the apical surface, and individual wells
received aliquots of Medium 199 containing 20% heat-
inactivated human serum with or without added mAbs as
indicated. After 24 hr of incubation, cultures were washed
twice in Medium 199, and control medium or medium con-
taining mAb was replenished. After a total time of 48 hr in
culture, samples were fixed for microscopic analysis. Differ-
ential interference contrast optics were used to quantitate the
number of mononuclear phagocytes (MP) that were beneath
the endothelial monolayer (11) in at least five high-power
fields per sample. Each experiment was conducted with six
replicates per parameter tested.
Skin Cultures. Human split-thickness skin was obtained
from the New York Firefighter’s Skin Bank (New York
Hospital-Cornell Medical Center) from cadavers within 24 hr
of death, or from patients undergoing plastic surgery, and was
authorized for use in research. Generally, dermatomes were
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approximately 300 mm thick, including both epidermis (about
100 mm) and a portion of the dermis. Skin was prepared and
cultured, and emigrated cells were quantitated as previously
described (7). Each explant was trimmed to 400-mm2 and
floated in 3–6 ml of culture medium. When used, mAbs or
verapamil (Sigma) were added to the culture medium at the
onset of culture, and cultures were incubated undisturbed until
the indicated day of analysis. Verapamil was prepared as a
concentrated stock in methanol. Final methanol concentration
in cultures was 0.03% (volyvol).
Immunostaining and Flow Cytometry. Skin explants were
separated into epidermal and dermal sheets by treatment with
0.5 M ammonium thiocyanate for 20 min at 37°C (12).
Alternatively, skin samples were snap-frozen in OCT com-
pound (Miles) and then used for the preparation of thick
sections (approximately 100 mm) cut parallel to the epidermis
(6) or thin cross-sections (10 mm). After either procedure,
sheets of skin were fixed in acetone for 5 min before staining.
Sheets of epidermis or thick sections were incubated overnight
at 4°C in Eppendorf tubes with Cy3-conjugated goat anti-
mouse IgG (1:200; Jackson ImmunoResearch), 1:20 fluores-
cein isothiocyanate-conjugated anti-MHC II (Becton Dickin-
son), or anti-MHC II 9.3C9 hybridoma supernatant. Tissues
were washed three times in PBS containing 1% Tween 20, 15
min each at room temperature. For detection of 9.3C9 when
it was used, Cy3-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch) was added for 2 hr at 4°C, followed by three
washes as just described. Staining for flow cytometry was
carried out as previously detailed (7).
In some experiments, explants were incubated in dispase II
(Boehringer Mannheim) for 45 min at 37°C to separate the
epidermis from dermis. Pieces of epidermis were submerged in
0.05% trypsiny0.53 mM EDTA for 45 min. Single cell suspen-
sions were generated by gently pressing epidermal pieces
through a fine mesh. Aliquots of digested cells were incubated
with fluorescein isothiocyanate-labeled anti-MHC II for 30
min on ice, washed twice, and analyzed by flow cytometry.
Some samples were labeled for two-color flow cytometry using
R-phycoerythrin-conjugated anti-CD86 (PharMingen).
Immunoblots. Emigrated DC were purified by negative
selection. Anti-CD3 mAb was incubated with emigrated cells,
and T lymphocytes were removed by using anti-mouse IgG-
conjugated magnetic beads (Dynal). The purity of the resulting
population was verified by flow cytometric evaluation after
staining with phycoerythrin-conjugated anti-MHC II (Becton
Dickinson). Microsomal membranes from 5 million thus pu-
rified DC, 25 million PBMC, or 5 million HUVEC were
prepared as described (13), subjected to SDSyPAGE (4–12%
gradient gel) under reducing conditions, and electroblotted
onto a nitrocellulose membrane. The membrane was probed
with 5 mgyml of C219 anti-MDR-1 mAb (Centocor) and
visualized by using peroxidase-conjugated anti-mouse IgG,
followed by ECL substrate (Amersham).
Eff lux Assays. A previously published method to detect
functional MDR-1 (14) was used with minor modifications.
Emigrated cells were incubated in RPMI medium 1640 con-
taining 20 ngyml of DiOC2 (Molecular Probes) for 15 min at
37°C, washed twice in ice-cold medium, resuspended in 10%
fetal bovine serumyRPMI medium 1640 containing no addi-
tives or with addition of 10 mgyml of UIC2 mAb (Coulter).
After 90 min of incubation at 37°C, cells were washed and
immediately placed on ice for labeling with phycoerythrin-
conjugated anti-MHC II mAb and analysis by flow cytometry.
RESULTS
Role of MDR-1 in Basal-to-Apical Transendothelial Migra-
tion of MP. Our attention was drawn to MDR-1 by a set of
observations with blood monocytes, now known to be a
precursor of DC when appropriately stimulated with cytokines
(15–19). In these initial experiments, we examined the migra-
tory behavior of monocytes in an in vitro model of the blood
vessel wall consisting of HUVEC grown on type I collagen gels
(10, 11). Human blood monocytes, which express MDR-1 (ref.
20 and data not shown), transmigrate across the confluent
endothelium and enter the collagenous substrate. This initial
migration into the collagen, which is completed within 1 hr,
was unaffected by the addition of anti-MDR-1 mAb, but was
partially blocked by mAbs against the b2 chain of integrins
(CD18) and CD31, as described (10, 11) (Fig. 1A).
After a brief residence in the collagen, a majority of
subendothelial MP retraverse the overlying, intact endothe-
lium with a t1/2 of 24–48 hr (21). This reverse transendothelial
migration was not prevented by mAb to CD18 or CD31 (Fig.
1B). However, screening of mAbs (.100) submitted to the
VIth International Workshop for Human Leukocyte Differ-
entiation Antigens revealed that neutralizing mAbs to MDR-1
strongly inhibited reverse transmigration. UIC2 (22), 4E3 (23),
and MRK16 (24) against extracellular domains of MDR-1
inhibited reverse transmigration by 61%, 64%, and 78%,
FIG. 1. Effect of anti-MDR-1 mAbs on transendothelial migration
of MP. (A) Monocytes were allowed to migrate across endothelial
monolayers with or without addition of anti-MDR-1 mAb MRK16, or
mAb to the b2 integrin (IB4) or CD31 (hec 7). Cultures were incubated
for 1.5 hr. (B) In experiments to examine their subsequent basal-to-
apical transmigration, monocytes were allowed to accumulate beneath
the endothelium in the absence of added mAb. Then monolayers were
washed, and individual wells received aliquots of culture medium with
or without added mAbs [all IgG2a; MRK16 used as F(ab9)2 fragments]
at the indicated concentrations. In some samples, PBMC were prein-
cubated with MRK16 or isotype-matched control mAb hec 1 against
cadherin 5 (Pre-MRK16 and Pre-Hec 1) before addition to the
endothelium. After 48 hr, cultures were fixed for analysis. Data are
plotted relative to control levels of reverse transmigration (no mAb
added), in which 50% of the subendothelial MP retraverse the
endothelium in 48 hr. Bars represent means 6 SD from 3–10 exper-
iments.
































respectively (Fig. 1B). MRK16, used here as F(ab9)2 fragments,
was the most potent blocking mAb, exhibiting maximal levels
of inhibition using as little as 0.5–1.0 mgyml. C219 (25), which
binds an intracellular epitope of MDR-1, had no effect.
Preincubation of monocytes with MRK16 and subsequent
removal of unbound mAb before addition of these cells to the
endothelium blocked reverse transmigration as well as when
the mAb was present continuously during the assay (Pre-
MRK16, Fig. 1B). No other mAbs screened inhibited reverse
transmigration, except one against tissue factor, whose possi-
ble specific role in reverse transmigration is currently under
investigation.
Role of MDR-1 in Mobilization of DC and T Lymphocytes
from Skin. During reverse transmigration, MP migrate
across endothelium in a basal-to-apical direction, a move-
ment that is reminiscent of the normal trafficking of DC
from the periphery into afferent lymphatics. We therefore
applied a panel of mAbs, including those against MDR-1, to
cultured human skin explants. Appearance of DC and T
lymphocytes in the culture medium of the explants was
reduced by 71% 6 9%, and 79% 6 16% when the skin was
incubated in the presence of MRK16 at concentrations of 2
and 10 mgyml, respectively (Fig. 2). Verapamil, a drug that
antagonizes MDR-1 transport (26) reduced DC and T
lymphocyte accumulation in the culture medium by 50% 6
13% at 10 mgyml (20 mM) (Fig. 2). The anti-MDR-1 mAb
UIC2 also blocked migration, by 70% 6 9% when used at 2
mgyml (Fig. 2). Isotype-matched mAbs that did not inhibit
migration included nonbinding control mAb hec1 against
cadherin 5 (11) and binding control mAb W6y32 against
MHC I. DC express CD18 and CD31, but mAbs against these
established leukocyte-endothelial cell adhesion molecules
did not block their migration (Fig. 2). Under all conditions,
the cellular content of emigres ranged from 40% to 60% DC,
with the remaining population being T lymphocytes. Thus,
antagonists of MDR-1 blocked migration of DC and T
lymphocyte uniformly. Cell viability in all groups was .90%,
as assessed by trypan blue exclusion.
Expression of MDR-1 by DC. T lymphocytes are known to
express MDR-1 (14, 20, 27), but its expression by DC has not
been reported previously. In some experiments, skin was
cultured in the presence of MRK16 for 2 days, as for
migration analysis. Then staining was carried out on sections
prepared from snap-frozen skin, applying only anti-mouse
Cy3-conjugated detection antibody (Fig. 3). Immunostaining
for MDR-1 was observed on DC in the epidermis (Fig. 3 A
and C) and dermis (not shown). The same cells also stained
positively for the DC marker MHC II (Fig. 3 B and C). A
minority of MHC II1 cells in the epidermis and dermis were
found that did not clearly express MDR-1. A similar pattern
of MDR-1 expression was observed in explants of skin that
were not cultured (day 0, not shown). No cell types in the skin
other than DC or T cells, such as keratinocytes or fibroblasts,
showed positive staining for MDR-1. This approach illus-
trates not only the presence of MDR-1 on epidermal DC in
situ, but also demonstrates that mAb applied during culture
gains sufficient access to the epidermis. Skin incubated with
isotype-matched control mAb hec 1 did not show positive
staining.
Flow cytometric analysis of the cells that emigrated from
control explants using double labeling with anti-MDR-1 (using
either MRK16 or UIC2) and anti-MHC II mAbs demonstrated
high levels of MDR-1 on all DC in some experiments (Fig. 4A)
or on a majority, but not all, DC in other experiments (Fig. 4B).
The fraction of DC staining positively was always greater than
the fraction of positively stained subset of T lymphocytes (Fig.
4C).
Expression of authentic MDR-1 by DC was evident in two
assays. To document expression of functional MDR-1 (28), DC
were loaded with a synthetic, f luorescent substrate for MDR-1,
DiOC2. At 37°C, but not 4°C, DC transported this substrate
into the surrounding medium, showing a log decrease in
fluorescence intensity (Fig. 4D), and this eff lux was inhibited
by anti-MDR-1 mAb UIC2 (Fig. 4D). To identify MDR-1
molecules in DC, crude membranes were prepared and im-
munoblotted by using anti-MDR-1 mAb C219. Two bands of
approximately 170–180 kDa, the reported molecular mass of
MDR-1, were identified (Fig. 4E). This pattern of reactivity
was similar to that seen in membranes from PBMC and was not
observed in HUVEC (Fig. 4E), which do not express MDR-1.
Neither extracellular expression of MDR-1 nor efflux of
DiOC2 were observed in fully mature DC (19) that were
differentiated in culture from monocytes (data not shown).
Thus, expression of MDR-1 by DC appears to be regulated by
environmental or maturational events.
Effect of MDR-1 Antagonists on Maturation and Retention
of DC in Epidermis. To examine the step at which emigration
of DC from the explants was inhibited by anti-MDR-1 mAb,
epidermal and dermal sheets prepared from cultured skin
explants were stained for MHC II (29, 30). Compared with the
number present at the onset of culture (Fig. 5 A and B), the
number of DC remaining in the epidermis after three days of
culture under control conditions was decreased by 56% (Fig.
5 A and C). In explants cultured in the presence of MRK16
(Fig. 5 A and D), UIC2 (Fig. 5A), or verapamil (Fig. 5A), a
more limited reduction in DC density of 13%, 11%, and 25%,
respectively, were observed. Thus, antagonism of MDR-1
results in retention of DC in the epidermis.
Maturation accompanies migration of DC from the epider-
mis. In cultures treated with anti-MDR-1 mAb, some DC
FIG. 2. Effect of anti-MDR-1 mAb on emigration of DC and T
lymphocytes from skin explants. Explants of human skin were floated
in culture medium without added mAb (n 5 10) or in medium
containing anti-MDR-1 mAbs MRK16 (n 5 10) or UIC2 (n 5 3),
anti-cadherin 5 mAb hec 1 (n 5 5), anti-CD31 mAb hec 7 (n 5 5),
anti-MHC I mAb W6y32 (n 5 3), anti-CD18 mAb IB4 (n 5 2),
verapamil (n 5 5), or the vehicle control for verapamil 0.03% methanol
(Vehicle, n 5 3). After 3 days of incubation, DC and T lymphocytes
that appeared in the culture medium were collected and counted as
previously described (7). Each condition was tested in triplicate; n 5
number of experiments in which condition was included. The number
of emigrated cells recovered from individual control explants was
typically 5 3 105. To compare data from different experiments, the
mean number of emigrated cells in the absence of added mAb in each
experiment was set equal to 1.0, and relative values were obtained for
the remaining data.
































retained in the epidermis appeared morphologically similar to
epidermal DC before the onset of culture (compare Fig. 5 B
and D), but others showed evidence of maturation resembling
that observed under control conditions (Fig. 5C and data not
shown), including an increase in cell size and greater intensity
of staining for MHC II (4, 29, 30). Flow cytometric analysis of
DC enzymatically removed from the epidermis after culture in
the presence of anti-MDR-1 mAb MRK16 or under control
conditions indicated that the maturation of DC was not
inhibited by anti-MDR-1, as exemplified by the up-regulation
of MHC II (Fig. 6) and CD86 (not shown). Thus, antagonism
of MDR-1 strongly impedes the migration of DC, but only
inconsistently or neglibly suppresses their maturation. How-
ever, we cannot exclude the possibility that some aspects of
maturation not examined here were affected by antagonists of
MDR-1.
DISCUSSION
In this study, we initially identified mAbs to MDR-1 as potent
inhibitors of basal-to-apical transendothelial migration of MP
in an in vitro model of a vessel wall. The profound effect of
anti-MDR-1 mAbs in this model contrasted with the lack of
inhibition observed when approximately 100 other mAbs
against HUVEC or MP surface proteins were applied, under-
scoring the specificity of the effect seen with the use of
anti-MDR-1 reagents. A previous study postulated that reverse
transmigration in this model may mimic the migration of
leukocytes into lymphatic vessels (21), because both processes
involve basal-to-apical transmigration from tissues across en-
dothelium. Accordingly, when we added MDR-1 antagonists
to cultured explants of human skin, from which DC emigrate
via lymphatic vessels (6), we observed a specific inhibition of
their mobilization. The close correlation between our findings
in the two models suggest that the vessel wall model may be a
simple, useful tool for future use in further identifying molec-
ular events that regulate migration into authentic lymphatic
vessels.
The mechanism by which MDR-1 acts to facilitate migration
remains unclear. It is unlikely that MDR-1 acts as a mediator
of adhesion. Before leaving the epidermis, DC down-regulate
E-cadherin (31), allowing retraction from neighboring kera-
tinocytes. In the presence of anti-a6 mAb, epidermal DC
up-regulate MHC II and retract from neighboring keratino-
cytes (32), but fail to migrate out of the epidermis. Another
adhesion molecule, CD44, also is used by DC during mobili-
zation from the epidermis (33). As with anti-a6, we found that
up-regulation of MHC II was not blocked by anti-MDR-1.
However, our finding that epidermal DC generally maintained
their interdigitating appearance in the presence of anti-
MDR-1 mAb, in contrast to our control cultures and the effect
of anti-a6 mAb (32), suggests that anti-MDR-1 may interfere
with a signal that directs DC to release from the epidermis.
Based on its well-known action as a membrane transporter,
MDR-1 likely mediates the translocation of a soluble, endog-
enous substrate(s), as yet unidentified, that regulates migra-
tion. MDR-1 can transport a wide variety of synthetic mem-
brane lipids from the inner to the outer leaflet of the plasma
membrane (34). However, the identity of a possible natural
lipid substrate is still uncertain. Two candidate substrates,
ceramide and prostaglandin E2, are known to affect matura-
FIG. 4. Expression of functional MDR-1 by emigrated DC. (A-C)
MDR-1 expression in emigrated skin cells was examined by flow
cytometry by using double staining with anti-MDR-1 mAb and the DC
lineage marker MHC II (A and B) or the T lymphocyte lineage marker
CD3 (C). Quadrants were marked based on the level of f luorescence
intensity observed in samples stained with negative control mAbs. (D)
For studies measuring efflux, emigrated cells were loaded with the dye
DiOC2 (dashed line, no dye added) and cultured at 37°C for 90 min
without addition of mAb (filled profile), in the presence of UIC2 mAb
(bold line), or kept at 4°C for this duration (thin line). Analysis of
eff lux in the DC fraction of emigrants was assessed by double labeling
with phycoerythrin-conjugated anti-MHC II mAb for flow cytometry.
Figure shown was gated on MHC II1 cells. (E) Membranes prepared
from purified, emigrated DC, PBMC, or HUVEC were immunoblot-
ted with anti-MDR-1 mAb C219. Numbers to the left of bands are
molecular weight markers.
FIG. 3. Expression of MDR-1 in situ by DC. (A) Epidermis derived from explants cultured with anti-MDR-1 mAb MRK16 were fixed, and
Cy3-conjugated anti-mouse IgG was added to detect expression of MDR-1 (red). Addition of Cy3-labeled detection antibody to skin incubated in
the presence of nonbinding control mAb (hec1) showed no staining (not shown). The section shown was cut parallel to the epidermal basement
membrane. (B) Immunostaining of same sample using fluorescein isothiocyanate-conjugated anti-MHC II mAb (green). (C) Doubly exposed frame
to examine colocalization (yellow) of MDR-1 and MHCII. (Bar is 10 mm.)
































tion and activation of DC (35, 36). Another proposed substrate
(34), platelet-activating factor, is chemotactic for DC in vitro
(37).
MDR-1 also may transport endogenous polypeptides, as do
a number of its homologs (38). In accord with a role in protein
trafficking, functional MDR-1 appears to be required for
optimal secretion of the polypeptide cytokine interleukin (IL)
2, and possibly other cytokines (39, 40). IL-1b mediates the
migration of epidermal DC from human skin explants in
response to contact allergens (41). In murine models of contact
sensitivity, the cytokines IL-1b and tumor necrosis factor
(TNF) a are required for the migration of epidermal DC to
lymph nodes (42, 43). In these animals, neutralizing anti-
TNF-a mAb blocks the migration of epidermal DC, but not
up-regulation of MHC II. Moreover, just as in our studies, DC
retained in the epidermis by anti-TNF-a remained interdigi-
tated among surrounding keratinocytes (43). The possibility
that MDR-1 activity is necessary for the secretion of IL-1b or
TNF-a is under investigation.
Induction or up-regulation of MDR-1 in cancerous cells
leads to drug resistance, a major obstacle in chemotherapeutic
treatment strategies (9). Antagonists of MDR-1 are used
clinically to combat the drug-transport activity of MDR-1 with
the aim of improving the treatment of xenobiotic-resistant
cancers (44). Prophylactic treatment with anti-MDR-1 re-
agents even in the absence of concurrent chemotherapy also
has been proposed (44). Recently, other approaches that
harness the antigen-presenting capacity of DC to enhance
immune rejection of cancerous cells have emerged as poten-
tially potent anticancer regimens (45, 46). Our findings, im-
plicating a role for MDR-1 in the mobilization of DC to lymph
nodes, highlight the wisdom of temporally segregating anti-
MDR-1 treatments to suppress drug resistance from immu-
notherapy targeting DC, because antagonism of MDR-1 may
limit successful initiation of immune responses.
This conclusion contrasts with the findings of Schinkel et al.
(47), who report that transgenic mice lacking mdr-1-type
p-glycoproteins (mdr1ay1b2/2) have no apparent physiologic
defects and, therefore, suggest that antagonism of p-
glycoproteins during cancer treatments should not interfere
with physiologic functions. However, DC function and migra-
tion were not specifically analyzed in these mice. Routine
histologic analysis of lymph nodes appeared normal. Our
findings suggest that immunologic function in mdr1ay1b2/2
mice needs further assessment. It is possible, too, that impor-
tant differences in function and representation by functionally
FIG. 5. Retention of DC in the epidermis after treatment with
MDR-1 antagonists. (A) Epidermal sheets were stained with anti-
MHC II mAb to enumerate DC before the onset of culture or after 3
days of culture in the absence of mAb (no mAb, n 5 7), or in the
presence of anti-cadherin 5 mAb hec 1 (n 5 3); anti-MHC I mAb
W6y32 (n 5 3); anti-CD31 mAb hec 7 (n 5 3); anti-MDR-1 mAb
MRK16 (n 5 6); anti-MDR-1 mAb UIC2 (n 5 1); verapamil (n 5 2);
or the vehicle control for verapamil 0.03% methanol (Vehicle, n 5 1).
n 5 number of experiments in which each condition was examined. DC
were counted from en face examinations of epidermal sheets in 16–20
high-power fields per experiment. Percent reduction in DC density was
calculated by comparing the number of DC in cultured explants to the
mean number present in a portion of the same skin sample before
culture (typically 75 cellsyfield). (B–D) Photomicrographs show the
distribution of DC within the epidermis before culturing of explants
(B), after 3 days of culture under control conditions (no mAb) (C), and
after 3 days of culture in the presence of MRK16 (D). (Bar is 50 mm.)
FIG. 6. Effect of anti-MDR-1 mAb on the maturation of DC. The
levels of MHC II expressed by epidermal DC were analyzed in gated
epidermal suspensions by flow cytometry before the onset of culture
(Day 0) or after 3 days of culture in the absence of mAb or in the
presence of MRK16. Single cell suspensions of the epidermis were
prepared by digestion with dispase followed by trypsin. Keratinocytes
and other skin cells were excluded from the analysis by setting a gate
to include only MHC II1 cells.
































redundant molecules exist between human and murine p-
glycoproteins.
Based on the present work, we propose that MDR-1 acts as
an upstream component in a cascade of events that regulates
traffic of leukocytes, particularly DC, out of tissues via lym-
phatic conduits. These data, in addition to demonstrating a
role for MDR-1 beyond protection against xenobiotic com-
pounds, stand to serve as a springboard in the identification of
physiologic substrates for MDR-1 and in furthering the study
of mechanisms that initiate T lymphocyte-dependent immune
responses.
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